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Introduction
Chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) has become the premier technology for profiling the genome-wide localization of chromatinbinding proteins, including transcription factors and histones with various modifications [1, 2] . An important downstream analysis of ChIP-seq data is to identify the genomic regions that are associated with differential binding intensities between different cellular contexts, which is essential to understanding the underlying mechanisms orchestrating the dynamics of gene expression program during various biological processes, including development and the onset of disease [3] [4] [5] . With the decrease of sequencing costs, researchers now incline to perform differential ChIP-seq analysis between groups of samples. On one hand, when the samples of each group are biological replicates for the same ChIP-seq experiment, differential analysis on group level can achieve much better specificity and sensitivity than between individual samples [6] . This improvement is especially vital for comparing ChIP-seq samples from heterogeneous tissues or closely related cell lineages [7] [8] [9] . On the other hand, when analyzing ChIP-seq profiles for tissues or cells obtained from different individuals, researchers may choose to classify them according to the age, sex, health status or disease subtype of each donor, and then perform differential analysis between groups of profiles to identify differential binding events associated with the group characteristics. This analysis is of particular interest in the studies of personal epigenomes, where fluctuations of histone modification levels across humans are often of functional importance and are best understood on population level [10] [11] [12] [13] .
Despite the importance of differential ChIP-seq analysis on group level, it remains a highly challenging computational task to reliably assess on a genome-wide scale the statistical significances of observed differences in ChIP-seq signal intensities between groups of samples, owing to the high level of noise and variability intrinsic to ChIP-seq data [6, 14] . In general, the success of a group-level differential ChIP-seq analysis relies on a robust approach for normalizing multiple ChIP-seq samples, as well as a sophisticated statistical model for accurately assessing the variability of ChIP-seq signals across samples of the same group (referred to as within-group variability) [15, 16] . Here we present a new computational tool for differential ChIP-seq analysis between groups of samples. The new tool, named MAnorm2, has made specific efforts to tackle the above two challenges in a manner that accounts for ChIP-seq data specific characteristics.
Regarding normalization, in practice, signal-to-noise (S/N) ratio can vary significantly across different ChIP-seq samples [6, 16] , which increases the difficulty of normalization.
We previously developed MAnorm for normalizing a pair of ChIP-seq samples. It alleviates the problem of S/N ratio by using common peaks (genomic regions enriched with ChIPseq reads) of the two samples to infer a reference model for globally normalizing ChIPseq signals [17] . This strategy has also been exploited by later methods for differential ChIP-seq analysis [18] . In MAnorm2, we extended MAnorm to normalization of any number of ChIP-seq samples. We further incorporated a hierarchical strategy into the normalization of groups of samples to account for the similarity structure among samples.
Specifically, by first normalizing samples separately within each group and then performing a between-group normalization, MAnorm2 could improve both the unbiasedness and robustness.
As for assessing within-group variability, in the field of differential RNA-seq analysis, the strategy of borrowing information between genes with similar expression levels under an empirical Bayes framework has been adopted by several cutting-edge methods, including limma-trend, voom and DESeq2 [19] [20] [21] . Among them, limma-trend fits a mean-variance curve (MVC) and squeezes gene-wise variance estimates towards the curve; voom is similar to limma-trend except that it encodes the fitted MVC into the precision weights of different measurements; DESeq2 uses the negative binomial distribution to model read counts and aims at fitting a mean-dispersion curve (MDC). In practice, these methods borrow strength between genes to improve variance/dispersion estimation, which could compensate for the lack of sufficient replicates. The same principle applies to ChIP-seq data as well, and many studies have directly applied these methods to differential ChIPseq analysis [13, [22] [23] [24] . Despite the usefulness of modeling mean-variance/dispersion trend under an empirical Bayes framework, no methods exploiting this strategy have been specifically developed for ChIP-seq data. As ChIP-seq data are typically associated with much higher noise level and variability than RNA-seq data, the statistical models originally designed for differential RNA-seq analysis may not be flexible enough to account for the characteristics of ChIP-seq data.
One problem is that the above RNA-seq methods derive the mean gene expression levels for fitting an MVC/MDC by taking the average across all individual samples, disregarding their group labels. This strategy generally applies well to differential RNA-seq analysis, since in most cases the vast majority of genes are expected to have nondifferential expression between biological conditions. For differential ChIP-seq analysis, however, the strategy may considerably bias the resulting MVC/MDC owing to the abundance of differential ChIP-seq signals. In practice, differential protein-binding events can be abundant even between very similar cellular contexts [10, 25] . One of the reasons is that the activity of regulatory elements, especially those at distal regions, is generally more variable across cellular contexts than is gene expression [10, 26, 27] . Another problem is that the RNA-seq methods derive a single variance/dispersion estimate for each gene, without explicitly modeling the difference in within-group variability between different groups. In practice, however, within-group variability of ChIP-seq signals could vary significantly across groups. For instance, when comparing ChIP-seq profiles between normal individuals and cancer patients, the within-group variability in the cancer group is often much higher than that in the normal group. In MAnorm2, we have made specific efforts to address these concerns. In particular, we resolve the two problems by deriving mean and variance estimates separately within each group of samples, adjusting the variance estimates from different groups based on the global within-group variability of each group, and pooling the resulting mean-variance pairs into a regression process.
We compared the performance of MAnorm2, limma-trend, voom and DESeq2 on a number of real ChIP-seq data sets. For each differential ChIP-seq analysis that we conducted, MAnorm2 performed as well or better than the other three methods, with the improvement in performance being most dramatic when the two groups of samples being compared had distinct global within-group variability. We also made a comparison between MAnorm2 and two existing methods (ChIPComp [18] and PePr [28] ) for differential ChIP-seq analysis, and found they were clearly outperformed by MAnorm2.
Results
Hierarchical normalization for groups of ChIP-seq samples To facilitate the understanding of the working principle of MAnorm2, we first give a brief description of some of its basic concepts. An MAnorm2 analysis starts with a count matrix and an occupancy matrix. The rows and columns of both matrices correspond to a predefined list of genomic intervals and a set of ChIP-seq samples, respectively. For each genomic interval in each sample, the count matrix records the number of sequencing reads mapped to the interval, and the occupancy matrix uses a binary variable to indicate whether the interval is enriched with reads (i.e., whether it is a peak region). Formally, we refer to a genomic interval as occupied by a ChIP-seq sample if the interval is enriched with reads in the sample.
For each MAnorm2 analysis performed in this study, we compiled the list of genomic intervals by separately calling peaks for each related ChIP-seq sample, merging all the resulting peaks, and dividing up broad merged peaks into consecutive genomic bins (narrow ones were left untouched). We then determined the occupancy status of each resulting genomic interval for each sample based on the overlap between the interval and the peaks identified for the sample. See Methods for details about the construction of input matrices of MAnorm2, but note that the MAnorm2 machinery is independent of the exact way of coming up with a list of genomic intervals and defining their occupancy states.
We previously developed MAnorm for pairwise comparison of ChIP-seq samples. It normalizes two individual samples by removing the overall M-A trend (M and A values refer to log2 fold change and average log2 read count, respectively) observed at their common peaks, based on the assumption of no global changes of protein-binding intensities at these regions [17] . MAnorm has been shown to give a better performance in handling ChIP-seq samples with distinct S/N ratios than the methods originally designed for normalizing microarray and RNA-seq data [16, 17] . In MAnorm2, we retained the core assumption of MAnorm, and we further devised a hierarchical scheme for the normalization of groups of samples to take advantage of the similarity structure among samples.
Here we use the normalization of H3K4me3 ChIP-seq data for two human lymphoblastoid cell lines (LCLs) as an example. The two LCLs, referred to as GM12891 and GM12892, were derived from different Caucasian individuals, and each cell line was associated with three biological replicates (data obtained from Kasowski et al. [10] ). In the hierarchical normalization process, MAnorm2 first separately normalizes the replicates for each LCL and then applies a between-group normalization (Fig. 1A) . For the first step, MAnorm2 selects one sample from each group as its baseline, and repeatedly normalizes every other sample of the group against that baseline. Specifically, to normalize each nonbaseline sample against the corresponding baseline sample, MAnorm2 applies a linear transformation to the log2 read counts of the non-baseline sample, such that the M-A trend observed at the common peak regions of the two samples is removed (see Methods; note also that MAnorm2 considers the genomic intervals that are occupied by both samples to be their common peak regions). For the second step, MAnorm2 creates a reference ChIPseq profile for each LCL by taking the average across all of its replicates (using normalized log2 read counts determined in the first step), and re-applies the above procedure for within-group normalization to the resulting two reference profiles. Then, the linear transformation derived for the non-baseline reference profile is equally applied to each individual replicate of the LCL it represents. The only technical problem of this approach is that we need to determine the occupancy states of genomic intervals for each reference profile (or equivalently, each group of samples). In this study, we considered a genomic interval to be occupied by a group of samples if it was occupied by at least one sample in the group.
After completing the entire normalization process, we found that the M-A trend at the common peak regions of each pair of samples was largely eliminated, independent of whether the two samples came from the same group or whether they had ever been selected as baseline (Fig. 1B) . This finding indicated that the normalized ChIP-seq signal intensities were comparable across all six samples. And we could then quantify the fold changes of H3K4me3 levels between the two LCLs by calculating M values between their (normalized) reference profiles. Of note, the M values for LCL-specific peak regions were systematically biased towards the corresponding LCL (Fig. 1C) , which contrasted with the roughly symmetric distribution of the M values for common peak regions and supported the need to remove sample/group specific peak regions from "globally invariant" regions when performing a normalization.
Modeling mean-variance trend under an empirical Bayes framework After normalization, MAnorm2 models the normalized log2 read counts as following the normal distribution. This strategy is similar to the one employed by voom, except that voom first normalizes read counts (based on the total read count of each sample) and then applies log2 transformation [20] . For a differential analysis between two groups of samples, a simple and straightforward method would be to apply a t-test to the normalized signal intensities of each genomic interval. In practice, however, the number of ChIP-seq samples in each group is usually small (two or three for the data sets used in this study), which may compromise the statistical power of t-tests for identifying differential binding events, considering the large uncertainty of the variance estimate for each interval that is derived from a very limited number of signal measurements.
To tackle this problem, MAnorm2 borrows strength between genomic intervals with similar signal levels. Specifically, it calculates observed means and variances for individual intervals within each group of samples, adjusts the observed variances from different groups to make them comparable across groups, and pools the resulting mean-variance pairs into a regression process to fit an MVC ( Fig. 2A; H3K4me3 levels at promoter regions of genes are strongly correlated with their transcription levels, we defined, for the genomic intervals located at gene promoters, true differential ones as those that were linked with differentially expressed genes (DEGs), which were identified by applying DESeq2 [21] to the corresponding RNA-seq data. Using each of the statistics, we ranked the promoter intervals in order of evidence of having differential H3K4me3 levels between the two LCLs, and calculated the proportions of true discoveries among top ranked intervals ( The strategy of shrinking variance/dispersion estimates under an empirical Bayes framework has been adopted by several existing tools for differential RNA-seq analysis [20, 21] . Technically, these tools improve the adaptivity to data sets of various characteristics by empirically determining the shrinkage strength. Similarly, our MAnorm2 uses the hyper-parameter 0 d to effectively control the degree to which observed variances are squeezed towards MVC, and 0 d is estimated from the data set under analysis. Despite the wide use of this strategy, few studies have used concrete examples to demonstrate specifically how it contributes to the adaptivity of a method. In particular, the advantage of empirical Bayes shrinkage over using directly prior variances/dispersions is of much interest. Here, we applied MAnorm2 to differential ChIP-seq analysis in two scenarios where the associated variance structures were of different complexity, by incorporating H3K4me3 ChIP-seq data for two additional Caucasian LCLs (referred to as GM12890 and SNYDER, each associated with two biological replicates [10] ). In the first scenario, we compared the H3K4me3 samples of GM12890 with those of SNYDER. In the second scenario, we classified the total four LCLs into male and female ones to perform a between-sex comparison. Note that, for this analysis, we used a reference H3K4me3 profile to represent each LCL and conducted a two-versus-two comparison as in the first scenario. The variance structure in the second scenario is clearly more complicated than that in the first scenario, as the within-group variability in the second scenario is additionally associated with the epigenetic variation across human individuals [10] . This difference is also indicated by the distinct 0 d estimates derived by MAnorm2 in the two analyses ( 0 d estimates are 14.6 and 4.2 in the first and the second scenario, respectively). We then used the corresponding gene expression data to assess the performance of MAnorm2 and another variant of it, which is referred to as MVC-only and uses directly prior variances as the final variance estimates. In summary, while the performance of MVC-only is comparable with that of MAnorm2 in the first scenario, it is significantly outperformed by MAnorm2 in the second one ( Supplementary Fig. 1 ). These results suggest that MVC-only is only suited to data sets with a highly regular variance structure. They also explicitly demonstrate how empirical Bayes shrinkage for variance estimation improves the adaptivity of a method. See Supplementary Note 2 for a much more detailed discussion of this topic.
Comparing MAnorm2 with other empirical Bayes methods that account for meanvariance/dispersion relationship As mentioned above, the strategy of modeling mean-variance/dispersion trend under an empirical Bayes framework has been adopted by several methods that are initially developed for differential RNA-seq analysis (e.g., limma-trend, voom and DESeq2 [19] [20] [21] ), and many studies have applied them to differential ChIP-seq analysis by first processing ChIP-seq data into a regular count matrix [13, [22] [23] [24] . The primary differences between MAnorm2 and these RNA-seq methods relate to two considerations of MAnorm2: (Fig. 3A) .
We further performed all possible pairwise comparisons of H3K4me3 ChIP-seq data among the four LCLs (GM12890, GM12891, GM12892 and SNYDER). For each of the resulting six comparisons, we selected 100, 200 up to 1000 top ranked genomic intervals at promoter regions and examined the proportions of true discoveries among them. Figure   3B gives the true discovery proportions among 500 top ranked intervals achieved by each method. In detail, each method is associated with 60 proportions of true discoveries, and
MAnorm2 provides the best performance in 51 of the cases (including 2 cases where MAnorm2 ties with voom; Supplementary Fig. 2 ). These results support the necessity for taking the abundance of differential ChIP-seq signals into account when fitting an MVC.
To investigate the practical utility of the second consideration of MAnorm2, we performed a differential analysis of H3K27ac ChIP-seq data between normal human individuals and cancer patients. In practice, H3K27ac ChIP-seq profiles for cancer patients are typically associated with much higher variability than those for normal individuals, owing to the heterogeneity of cancer tissues/cells as well as the diversity of subtypes and stages of the disease. We first collected H3K27ac ChIP-seq data for three human chronic lymphocytic leukemia (CLL) cell lines (referred to as MEC1, OSU-CLL and CII) that are derived from different patients [13] . For the normal counterparts, we collected data for GM12891, GM12892 and SNYDER LCLs [10] , which were selected to match the sex composition of the CLL group. Note that all the LCLs and CLL cell lines are generated by using Epstein-Barr virus to transform primary B cells harvested from donors and, thus, the comparison between the LCL group and the CLL group makes clear biological sense.
Using MAnorm2, we normalized the H3K27ac ChIP-seq signals across the six cell lines.
Principle component analysis (PCA) on the resulting normalized signal intensities showed that the global within-group variability of the CLL group is indeed much higher than the LCL group (Fig. 4A) . We have also drawn a scatter plot that maps the observed means and variances (of normalized signal intensities) from each group (Fig. 4B) . Overall, data points from the CLL group have a clear tendency to lie above those from the LCL group, indicating an increased magnitude of signal variances associated with the CLL group.
Consistently, MAnorm2 derived an estimate of CLL LCL   about 3.66, indicating that the global within-group variability of the CLL group is over three-fold compared to the LCL group. The estimated ratio was then used by MAnorm2 to adjust the observed variances from the CLL group, and an MVC was subsequently fitted on the resulting mean-variance pairs from both groups (Fig. 4C) . The whole process is essentially to normalize observed variances from different groups, and MAnorm2 manages to integrate this normalization into a statistical model for the following differential analysis (see Methods). Again, based on the corresponding gene expression profiles, we defined true differential genomic intervals among the ones that were located at gene promoters, and we compared the rankings of promoter intervals provided by different methods (Fig. 4D) . We found that LCLs and CLL cell lines, we compared the ranking of genomic intervals at gene promoters provided by MAnorm2 with those from ChIPComp and PePr. Note that we have separately used each of two statistics derived by ChIPComp to rank intervals, which were p-value and the posterior probability for a fold change of ChIP-seq signal to be larger than 2 [18] .
We observed that MAnorm2 gives the highest proportion of true discoveries in all cases ( Fig. 5 and Supplementary Fig. 3 ). Together, these comparisons between MAnorm2 and the tools for differential ChIP/RNA-seq analysis demonstrate the power of modeling meanvariance trend under an empirical Bayes framework and indicate the usefulness of adapting this modeling strategy to the characteristics of ChIP-seq data.
Discussion
In the study, we developed MAnorm2 for quantitatively comparing groups of ChIP-seq samples. Technically, MAnorm2 is comprised of a hierarchical normalization scheme and an empirical Bayes model that exploits mean-variance relationship to improve variance estimates. We have demonstrated the standard workflow of each of the two parts for comparing two groups of samples, but both parts could be extended in several ways for practical ChIP-seq data analysis.
For the normalization part, the hierarchical scheme is designed for taking advantage of the similarity structure among samples. It could also increase the stability of normalization results by avoiding selecting a single baseline sample from many samples. In the study,
we have shown how to apply a hierarchical normalization to two groups of samples corresponding to different cellular contexts. In theory, the normalization method could be generalized to samples sorted into an arbitrary hierarchical structure. More specifically, by traversing the associated hierarchical tree from bottom to top, we could iteratively normalize the samples associated with each tree branch and create a reference profile to represent the branch. Similar to the two-group normalization, this normalization process always chooses the samples/profiles most resembling each other to normalize at each round of iteration. For practical data analysis, we expect that increasing the complexity of hierarchical tree to account for additional factors affecting the similarity structure among samples (e.g., batch effects) may help reducing normalization biases, especially for largescale studies where a great number of samples are involved [11, 12] .
As for the statistical model part, MAnorm2 uses a multivariate normal (MVN) distribution to model the normalized signal intensities of each genomic interval in each group of samples (in the study, normalized signal intensities derived from the normalization part of MAnorm2 were all normalized log2 read counts). Technically, for each interval in each group, the covariance matrix of the MVN distribution is expressed as a symmetric matrix (termed structure matrix) times a scalar that quantifies the within-group variability (see Methods). Although all the structure matrices used in this study were simply identity matrices, the users could use structure matrix to easily incorporate existing tools for modeling the precision weights of signal measurements from different samples as well as the correlations among the measurements [20, 29] , which, for example, may help dealing with ChIP-seq samples that are associated with distinct quality and/or batch effects. we found that MAnorm2 provided a much better ranking of the genomic intervals at gene promoters than the other two methods (Fig. 6A ). In addition, compared with ANOVA, MAnorm2 considerably increased the sensitivity for identifying differential intervals without sacrificing the specificity (Fig. 6B ).
The two parts of MAnorm2 are relatively independent of each other, and they both operate on continuous variables (thus, the input signal measurements of MAnorm2 are not limited to integers). Together, these properties make it easy to incorporate existing methods for adjusting for confounding factors into an MAnorm2 analysis. For example, MAnorm2 has not devised a specific method for correcting for background signals that are measured by input samples. In practice, the users could perform such a correction before invoking the normalization part of MAnorm2, by separately subtracting raw/normalized input read counts from each ChIP-seq sample [22, 28] or by modeling the relationship between background and ChIP-seq signals in a more sophisticated manner [18] . Another example relates to batch effects. Most existing tools for removing batch effects are initially developed for continuous measurements from microarray experiments [30, 31] . If the ChIP-seq data under analysis are found to be associated with serious batch effects, one could apply these tools to the normalized signal intensities from MAnorm2 before invoking its modeling part for the following differential analysis. 
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Methods

Data sets and preprocessing
H3K4me3 ChIP-seq data and RNA-seq data for four human lymphoblastoid cell lines (LCLs; GM12890, GM12891, GM12892 and SNYDER) derived from different Caucasian individuals were obtained from Kasowski et al. [10] . H3K27ac ChIP-seq data for GM12891, GM12892 and SNYDER LCLs were obtained from the same study. H3K27ac ChIP-seq data and RNA-seq data for three human chronic lymphocytic leukemia (CLL) cell lines (MEC1, OSU-CLL and CII) were obtained from Ott et al. [13] .
We started processing the ChIP-seq and RNA-seq samples with raw sequencing reads.
We first applied quality and adapter trimming to the 3' end of every raw read by using Trim
Galore [32] . The resulting ChIP-seq and RNA-seq reads were then aligned to the hg19 reference genome by bowtie [33] and STAR [34] , respectively. To avoid potential artefacts from PCR amplification [35] , we separately removed duplicates for each individual sample, which means we kept at most one read (for each single-end sequencing sample) or read pair (for each paired-end sequencing sample) at each genomic location. Note that the genomic location of each single read was considered to be the coordinate and strand of its 5' end in the reference genome, and the genomic location of each read pair was considered to be the coordinates of the associated two 5' ends in plus and minus strands respectively.
Processing read alignments and calling peaks for ChIP-seq samples
We separately identified peaks for each of the ChIP-seq samples by using MACS 1.4 [36] .
The '--shiftsize' parameter of MACS 1.4 controls the distance in bp by which the genomic coordinate of the 5' end of each aligned read is shifted downstream to reach the exact protein binding site, which is presumed to be the center of the underlying DNA fragment from which the read is sequenced. When using MACS 1.4, the single value specified for '--shiftsize' is universally applied to all reads, but the sizes of collected DNA fragments for sequencing do vary. To make full use of the parameter, for each aligned read pair of a paired-end sequencing sample, we inferred the center of the underlying DNA fragment as the midpoint between the coordinates of the associated two 5' ends, and the read pair was then converted into a single read whose 5' end lies upstream of the inferred center with an exact distance of 100 bp. We also noticed that the setting of '--shiftsize' could influence the resulting peak lengths. To unify the general peak length across different ChIP-seq samples, we have processed single-end sequencing samples in a similar manner.
Specifically, for each aligned read of a single-end sequencing sample, the associated DNA fragment center was inferred as the site lying downstream of the read's 5' end with a certain distance, which was half the fragment size used for size-selecting the library (this information was available for all the single-end ChIP-seq samples used in the study), and the read was then shifted such that the resulting 5' end lies exactly 100 bp upstream of the inferred center. Finally, for each processed ChIP-seq sample, peak calling was performed against the corresponding input sample with the parameters '-g hs --nomodel --shiftsize=100 --keep-dup=all' (we had already removed duplicates for each of the ChIPseq samples before applying the above processing). Note that input samples were available for all the ChIP-seq samples used in the study and they were processed in exactly the same way as the ChIP-seq samples. To be clear, all the differential ChIP-seq analyses presented in the study were based on the same processed read alignments as used for peak calling.
Input matrices of MAnorm2
For performing a differential analysis between two or more groups of ChIP-seq samples, MAnorm2 takes a count matrix and an occupancy matrix as input. The rows of both matrices correspond to a pre-defined list of genomic intervals, and their columns correspond to the involved ChIP-seq samples. For each genomic interval in each sample, the count matrix records the number of sequencing reads that fall within the interval, and the occupancy matrix uses a binary variable to indicate whether the interval is enriched with reads (or whether the interval is a peak region). Note that MAnorm2 refers to a genomic interval as occupied by a ChIP-seq sample if the interval is enriched with reads in the sample.
We have specifically developed a software package named MAnorm2_utils for integrating ChIP-seq data into a regular table suited as input of MAnorm2. For each MAnorm2 analysis performed in the study, we compiled the two input matrices by applying 
where mean and cov refer to sample mean and sample covariance, respectively, and _ indicates the quantities are calculated with respect to the common peak regions (i.e., the genomic intervals occupied by both samples). The solutions for  and  are given
where sd refers to sample standard deviation.
Modeling and normalizing groups of ChIP-seq samples
MAnorm2 models a group of ChIP-seq samples that have already been normalized by using the multivariate normal (MVN) distribution. Suppose X is an n m  matrix recording the normalized signal intensities (i.e., normalized log2 read counts) at n genomic intervals for m ChIP-seq samples belonging to the same biological condition.
Let i X be a column vector that represents the transpose of the -th i row of X . We
Here i  and i t are two unknown scalars that parametrize the mean signal intensity of interval i in this biological condition and the associated signal variation level, respectively;
1 is a column vector of ones; i S , termed structure matrix, is an m m  matrix designed for the convenience of incorporating existing tools for modeling the precision weights of signal measurements from different samples as well as the correlations among the measurements [20, 29, 39] . All structure matrices used in the study were simply identity matrices. MAnorm2 next derives mean and variance estimates by applying the generalized least squares method:  with a probability of one (i.e., they could be treated as the same random 
where
According to the theoretical deduction presented in Smyth et al. LCLs, we have also come up with a list of non-DEGs (Fig. 2C ), which were defined as the genes that had a DESeq2 p-value larger than 0.5 and a fold change (obtained also from DESeq2) less than 2.
Differential analysis of H3K27ac ChIP-seq data and RNA-seq data between LCLs and CLL cell lines
We performed a comparison between three LCLs (GM12891, GM12892 and SNYDER) and three CLL cell lines (MEC1, OSU-CLL and CII). For the differential analysis of H3K27ac ChIP-seq data, each of the LCLs was associated with two or three biological replicates, and each of the CLL cell lines was associated with a single ChIP-seq sample. 
